First Evidence of Treatment Benefit in Chagas Heart Failure
The combination of sacubitril and valsartan appeared superior to enalapril in the first randomized trial to generate high-quality evidence to support a drug treatment specifically for patients with heart failure caused by Chagas disease.
But the results from the trial PARACHUTE-HF were driven by reductions in levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), one component of the primary composite endpoint. Researchers noted only small, nonsignificant reductions in the primary endpoint’s harder clinical outcomes, including cardiovascular death and hospitalization for heart failure.
Even so, the data may help move the needle on treatment for the disease, according to lead investigator Renato Lopes, MD, of Duke University in Durham, North Carolina.
نظر دهید